PERSPECTA

News from every angle

← Back to headlines

Corcept Pharmaceuticals Sets 2026 Revenue Target and Awaits Drug Approval

Corcept Pharmaceuticals announced a revenue target of $1.1B-$1.2B for 2026, driven by the launch of Lifyorli which has reached 1,300 patients. The company is also awaiting a PDUFA decision for relacorilant on December 17.

29 Jul, 23:34 — 29 Jul, 23:34
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed1h ago

Corcept targets $1.1B-$1.2B 2026 revenue as Lifyorli launch reaches 1,300 patients and relacorilant awaits Dec. 17 PDUFA

Read full article →

Related Stories

Oldest Known Plague Outbreak Discovered in Siberia Dating Back 5,500 Years

just now

Physiotherapist Offers Advice on Healthy Bowel Movements

50m ago

Professor Advises on Health Benefits of Hot vs. Cold Coffee

55m ago

Portugal Lacks Integrated 'One Health' Strategy for Disease Prevention

1h ago